Companies / BOC Sciences / Monalizumab
BOC Sciences

Monalizumab | BOC Sciences

Monalizumab is a first-in-class immune checkpoint inhibitor that targets Natural Killer Group 2A (NKG2A). Monalizumab increased degranulation and IFN-_ production by NKG2A+ NK cell against HLA-E+ target cells, thereby promoting NK cell effector functions.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
  • See More